Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Tango Therapeutics, Inc.
STORM Therapeutics LTD
Novartis
Elpiscience Biopharma, Ltd.
Nkarta, Inc.
Polaris Group
Precision IO Group
USWM, LLC (dba US WorldMeds)
PharmaMar
SpringWorks Therapeutics, Inc.
Kumquat Biosciences Inc.
Deciphera Pharmaceuticals, LLC
Kivu Bioscience Inc.
Amgen
Tango Therapeutics, Inc.
EMD Serono
Verismo Therapeutics
Eli Lilly and Company
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Ascentage Pharma Group Inc.
Parabilis Medicines, Inc.
Hansoh BioMedical R&D Company
Bayer
Alpha Tau Medical LTD.
Iovance Biotherapeutics, Inc.
SpringWorks Therapeutics, Inc.
Turning Point Therapeutics, Inc.
Actuate Therapeutics Inc.
Zai Lab (Hong Kong), Ltd.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
GlaxoSmithKline
Novartis
Ipsen
Agenus Inc.
Fluidx Medical Technology, Inc.
Hoffmann-La Roche
Erasca, Inc.
CivaTech Oncology
Shanghai Pharmaceuticals Holding Co., Ltd
Cellectar Biosciences, Inc.
Inhibrx Biosciences, Inc
Ratio Therapeutics, Inc.
Kura Oncology, Inc.
QBiotics Group Limited
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
Zai Lab (Hong Kong), Ltd.